Flex Pharma Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Flex Pharma (FLKS) Tops Q2 EPS by 7c
August 2, 2017 7:38 AM EDTFlex Pharma (NASDAQ: FLKS) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $331 thousand versus the consensus estimate of $520 thousand.
For earnings history and earnings-related data on Flex Pharma (FLKS) click here.
... More